ClinicalTrials.gg
RecruitingNCT06205485NEO-RTUpdated Jul 14, 2026

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

A Phase 3 interventional study of Leucovorin and Oxaliplatin in Rectal Cancer, sponsored by Canadian Cancer Trials Group. Recruiting at 113 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Canadian Cancer Trials Group · Phase 3, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies testing leucovorin in Rectal Neoplasms — 3 open to participants now, 6 under way, 2 of them phase 3. Leucovorin · Rectal Neoplasms.

Planned enrollment
6th of 35
250 · median 57
Started
2024
the only one that year
Phase 3
6 of 36
1 open now
Registered
36th of 36
by date
Lead sponsor
1 of 36
Canadian Cancer Trials Group

Among the 36 studies testing leucovorin in Rectal Neoplasms, this one is the 6th largest by planned enrollment of the 35 interventional ones that give a count, is the only one that started in 2024, is one of 6 in phase 3, and was the 36th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

3 of the 36 studies testing leucovorin in Rectal Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About leucovorin

Leucovorin: first FDA approval 1952 (LEUCOVORIN CALCIUM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing leucovorin in Rectal Neoplasms, or all of them as a file.
02

Study summary

This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limited surgery? If radiation therapy is not given, is quality of life better?

Read the detailed description

This study is being done to find out if this approach is better or worse than the usual approach for early rectal cancer. The usual approach is defined as care most people get for early rectal cancer.

The usual approach for patients who are not in a study is surgery to remove the rectum or treatment with chemotherapy and radiation therapy, followed by surgery. There are several chemotherapy drugs approved by Health Canada that are commonly used with radiation therapy. For patients who get the usual approach for this cancer, about 90 out of 100 are free of cancer after 5 years.

If a patient decides to take part in this study, they will either get a combination of chemotherapy drugs called FOLFOX or CAPOX for up to 12 weeks or will get chemotherapy with radiation therapy for up to 6 weeks.

After finishing treatment, and even if treatment is stopped early, the study doctor will watch for side effects and determine which type of surgery would be best. After surgery, patients will be asked to come in every 4 months for 2 years, then every 6 months for an additional year. Then will be checked every year for 2 years. This means seeing the study doctor for up to 5 years after surgery. Patients may be seen more often if your study doctor thinks it is necessary.

03

Conditions studied

  • Rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed invasive, well-moderately differentiated rectal adenocarcinoma, mismatch repair proficient.
  • MRI stage cT1 not eligible for transanal surgery or cT2-T3ab*. * T3a: \<1mm depth invasion, T3b: 1-5mm depth of invasion.
  • cN0 stage based on pelvic MRI - including absence of radiographic evidence of mesorectal nodal , tumour deposits or extramural venous invasion (EMVI).
  • M0 stage based on no evidence of metastatic disease by CT imaging of chest, abdomen and pelvis.
  • Mid to low-lying tumour eligible for transanal excision in the opinion of the treating surgeon.
  • Medically fit to undergo radical TME surgery as per treating surgeon's decision.
  • Participant is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires in either English or French or Spanish.
  • Age of at least 18 years.
  • No to protocol chemotherapy.
  • Adequate normal organ and marrow function: ≥ x 10\^9/L; count ≥ 100 x 10\^9/L; \< 1.5 UNL, excluding Gilbert's syndrome; Estimated of ≥ 50ml/min
  • Patient must have an performance of \<2 (or Karnofsty ≥ 60%).
  • Must be accessible for treatment and follow-up
  • Males and females of must have agreed to use a highly effective method during and for 6 months after completion of chemotherapy.
  • -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.

Exclusion criteria

Exclusion Criteria:

  • Pathologic high-risk factors on diagnostic : high histologic grade (poorly differentiated), mucinous or signet ring histology.
  • Patients with visible pelvic sidewall nodes on MRI.
  • Patients with unequivocal determination of nodal disease that, in the opinion of the investigator, would prohibit protocol therapy administration.
  • Previous pelvic radiation for any reason, including brachytherapy alone.
  • Patients who have had primary lesion excised prior to enrollment. If a patient has had partial excision prior to enrollment, there must be gross residual disease endoscopically for patient to be eligible.
  • Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial.
  • Prior treatment for rectal cancer.
  • Patients with known dihydropyrimidine dehydrogenase deficiency (DYPD).
  • Potential trial participants should have recovered from adverse events of their most recent therapy/intervention prior to enrollment.
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, patients should be class 2B or better.
  • Any to undergo MRI imaging.
  • Presence of anterior lesions above or near peritoneal reflection rendering the patient ineligible for a transanal tumour excision.
  • T3 tumours invading or abutting the internal sphincter.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Active comparator
    FOLFOX OR CAPOX

    FOLFOX= Six cycles of modified FOLFOX consisting of leucovorin, oxaliplatin and bolus fluoruracil (optional), infusional fluorouracil. CAPOX= Capecitabine twice daily for 14 days and Oxaliplatin on day 1

    Drug: Leucovorin · Drug: Oxaliplatin · Drug: Fluoruracil · Drug: Capecitabine

  • Active comparator
    ChemoRT

    Standard dose of infusional 5-Fluorouracil/capecitabine and radiation

    Drug: Fluoruracil · Drug: Capecitabine · Radiation: Radiation

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical response rate upon re-staging

    Time frame: 6 years

  2. Quality of Life defined using the LARS score

    Time frame: 6 years

Secondary outcomes

  1. Total Mesorectal Excision (TME) Free Survival

    Defined as time from randomization to the time of TME attempt or performance, local recurrence after complete clinical response (cCR), or death from any cause

    Time frame: 6 years

  2. Disease Free Survival

    Defined as time from randomization to local recurrence/regrowth after cCR that cannot be salvaged with an R0 TM, M1 recurrence, or death

    Time frame: 6 years

  3. Overall Survival

    Among patients treated with induction chemotherapy versus chemoradiotherapy

    Time frame: 6 years

  4. Rate of downstaging to ypTO/1N0/X

    Time frame: 6 years

  5. Bowel function assessed by Low Anterior Resection Syndrome (LARS) Score

    Time frame: 6 years

  6. Bladder function assessed by EORTC QLQ-CR29 urinary frequency and urinary incontinence subscales

    Time frame: 6 years

  7. Other QoL functions assessed by subscales of FIQL

    Time frame: 6 years

  8. Other QoL functions assessed by subscales of EORTC QLQ-C30

    Time frame: 6 years

  9. Other QoL functions assessed by subscales of subscales of EORTC QLQ-CR29

    Time frame: 6 years

  10. Number and severity of adverse events utilizing CTCAE v5.0

    Time frame: 6 years

  11. Validate the magnetic resonance tumour regression grade (MR-TRG) in patients with T1-T3a rectal cancer

    Time frame: 6 years

07

Study locations

111 of 113 sites recruiting

Showing the first 100 of 113 sites across 2 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jan 2030, 67 months after the start.

Of 73 non-industry phase 3 interventional studies under Rectal Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 104. This study's planned 67 months is below that.

Counting every sponsor, half of 81 studies reached it within 59 months; a quarter within 37 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2023
First posted
Jan 16, 2024
StartActual
Jun 26, 2024
Primary completionEst.
Jan 30, 2030
CompletionEst.
Jun 30, 2030
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06205485
Lead sponsor
Canadian Cancer Trials Group
Responsible party
Sponsor
First posted
Jan 16, 2024
Start date
Jun 26, 2024
Primary completion
Jan 30, 2030 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Jul 14, 2026

Study contacts

Chris O'Callaghan
Contact
cocallaghan@ctg.queensu.ca
613-533-6430
Hagen Kennecke
study chair · Providence Portland Medical Centre, Portland, OR, USA
Carl Brown
study chair · St. Paul's Hospital, Vancouver, BC, Canada

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Leucovorin · Oxaliplatin

Start the discussion